Therapeutic approach to the patient with irritable bowel syndrome

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

This article reviews briefly the evidence to support current therapies in irritable bowel syndrome (IBS) and the novel therapeutic approaches on the threshold of clinical application. Fiber is indicated at a dose of at least 12 grams per day in patients with constipation-predominant IBS. Loperamide (and probably other opioid agonists) are of proven benefit in diarrhea-predominant IBS; loperamide may also aid continence by enhancing resting anal tone, but there is no evidence that it results in pain relief. In general, smooth muscle relaxants are best used sparingly, on an as-needed basis, because their overall efficacy is unclear. The 5-HT3 antagonist, alosetron, results in adequate relief of pain and improvements in bowel function in female nonconstipated patients with IBS. Psychotropic agents are important in relieving depression and are of proven benefit for pain and diarrhea in patients with depression associated with IBS. Further trials with selective serotonin reuptake inhibitors are awaited. Psychological treatments including hypnotherapy are less widely available but may play an important role in the relief of pain. In summary, current therapies targeted on the predominant symptoms in IBS are moderately successful. As the bowel sensorimotor and limbic system disturbances of IBS are more clearly understood, we should anticipate other pharmacologic approaches in the near future, including α-adrenergic agonists and 5-HT4 agonists. New therapies directed at treatment of the syndrome, rather than relief of symptoms, are needed. Copyright (C) 1999 Excerpta Medica Inc.

Original languageEnglish (US)
Pages (from-to)27-32
Number of pages6
JournalAmerican Journal of Medicine
Volume107
Issue number5 SUPPL. 1
DOIs
StatePublished - Nov 8 1999

Fingerprint

Irritable Bowel Syndrome
Loperamide
Pain
Therapeutics
Diarrhea
Serotonin 5-HT4 Receptor Agonists
Depression
Serotonin 5-HT3 Receptor Antagonists
Limbic System
Adrenergic Agonists
Hypnosis
Serotonin Uptake Inhibitors
Constipation
Opioid Analgesics
Smooth Muscle
Psychology

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Therapeutic approach to the patient with irritable bowel syndrome. / Camilleri, Michael.

In: American Journal of Medicine, Vol. 107, No. 5 SUPPL. 1, 08.11.1999, p. 27-32.

Research output: Contribution to journalArticle

@article{bf41e56359c44aa7bb73a1b9608cbac9,
title = "Therapeutic approach to the patient with irritable bowel syndrome",
abstract = "This article reviews briefly the evidence to support current therapies in irritable bowel syndrome (IBS) and the novel therapeutic approaches on the threshold of clinical application. Fiber is indicated at a dose of at least 12 grams per day in patients with constipation-predominant IBS. Loperamide (and probably other opioid agonists) are of proven benefit in diarrhea-predominant IBS; loperamide may also aid continence by enhancing resting anal tone, but there is no evidence that it results in pain relief. In general, smooth muscle relaxants are best used sparingly, on an as-needed basis, because their overall efficacy is unclear. The 5-HT3 antagonist, alosetron, results in adequate relief of pain and improvements in bowel function in female nonconstipated patients with IBS. Psychotropic agents are important in relieving depression and are of proven benefit for pain and diarrhea in patients with depression associated with IBS. Further trials with selective serotonin reuptake inhibitors are awaited. Psychological treatments including hypnotherapy are less widely available but may play an important role in the relief of pain. In summary, current therapies targeted on the predominant symptoms in IBS are moderately successful. As the bowel sensorimotor and limbic system disturbances of IBS are more clearly understood, we should anticipate other pharmacologic approaches in the near future, including α-adrenergic agonists and 5-HT4 agonists. New therapies directed at treatment of the syndrome, rather than relief of symptoms, are needed. Copyright (C) 1999 Excerpta Medica Inc.",
author = "Michael Camilleri",
year = "1999",
month = "11",
day = "8",
doi = "10.1016/S0002-9343(99)00279-X",
language = "English (US)",
volume = "107",
pages = "27--32",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "5 SUPPL. 1",

}

TY - JOUR

T1 - Therapeutic approach to the patient with irritable bowel syndrome

AU - Camilleri, Michael

PY - 1999/11/8

Y1 - 1999/11/8

N2 - This article reviews briefly the evidence to support current therapies in irritable bowel syndrome (IBS) and the novel therapeutic approaches on the threshold of clinical application. Fiber is indicated at a dose of at least 12 grams per day in patients with constipation-predominant IBS. Loperamide (and probably other opioid agonists) are of proven benefit in diarrhea-predominant IBS; loperamide may also aid continence by enhancing resting anal tone, but there is no evidence that it results in pain relief. In general, smooth muscle relaxants are best used sparingly, on an as-needed basis, because their overall efficacy is unclear. The 5-HT3 antagonist, alosetron, results in adequate relief of pain and improvements in bowel function in female nonconstipated patients with IBS. Psychotropic agents are important in relieving depression and are of proven benefit for pain and diarrhea in patients with depression associated with IBS. Further trials with selective serotonin reuptake inhibitors are awaited. Psychological treatments including hypnotherapy are less widely available but may play an important role in the relief of pain. In summary, current therapies targeted on the predominant symptoms in IBS are moderately successful. As the bowel sensorimotor and limbic system disturbances of IBS are more clearly understood, we should anticipate other pharmacologic approaches in the near future, including α-adrenergic agonists and 5-HT4 agonists. New therapies directed at treatment of the syndrome, rather than relief of symptoms, are needed. Copyright (C) 1999 Excerpta Medica Inc.

AB - This article reviews briefly the evidence to support current therapies in irritable bowel syndrome (IBS) and the novel therapeutic approaches on the threshold of clinical application. Fiber is indicated at a dose of at least 12 grams per day in patients with constipation-predominant IBS. Loperamide (and probably other opioid agonists) are of proven benefit in diarrhea-predominant IBS; loperamide may also aid continence by enhancing resting anal tone, but there is no evidence that it results in pain relief. In general, smooth muscle relaxants are best used sparingly, on an as-needed basis, because their overall efficacy is unclear. The 5-HT3 antagonist, alosetron, results in adequate relief of pain and improvements in bowel function in female nonconstipated patients with IBS. Psychotropic agents are important in relieving depression and are of proven benefit for pain and diarrhea in patients with depression associated with IBS. Further trials with selective serotonin reuptake inhibitors are awaited. Psychological treatments including hypnotherapy are less widely available but may play an important role in the relief of pain. In summary, current therapies targeted on the predominant symptoms in IBS are moderately successful. As the bowel sensorimotor and limbic system disturbances of IBS are more clearly understood, we should anticipate other pharmacologic approaches in the near future, including α-adrenergic agonists and 5-HT4 agonists. New therapies directed at treatment of the syndrome, rather than relief of symptoms, are needed. Copyright (C) 1999 Excerpta Medica Inc.

UR - http://www.scopus.com/inward/record.url?scp=0032693909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032693909&partnerID=8YFLogxK

U2 - 10.1016/S0002-9343(99)00279-X

DO - 10.1016/S0002-9343(99)00279-X

M3 - Article

C2 - 10588170

AN - SCOPUS:0032693909

VL - 107

SP - 27

EP - 32

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 5 SUPPL. 1

ER -